tetano
Editor, Senior Moderator
J Card Surg
. 2020 Jul 17.
doi: 10.1111/jocs.14867. Online ahead of print.
Extracorporeal membrane oxygenation and COVID-19: The causes of failure
Zargham Hossein Ahmadi[SUP] 1 [/SUP], Alireza Jahangirifard[SUP] 1 [/SUP], Behrooz Farzanegan[SUP] 2 [/SUP], Payam Tabarsi[SUP] 3 [/SUP], Zahra Abtahian[SUP] 4 [/SUP], Atefeh Abedini[SUP] 4 [/SUP], Mehrzad Sharifi[SUP] 1 [/SUP], Amir Naser Jadbabaei[SUP] 1 [/SUP], Yadollah Mafhumi[SUP] 4 [/SUP], Ali Moslem[SUP] 4 [/SUP], Marjan Sistani[SUP] 4 [/SUP], Sahar Yousefian[SUP] 4 5 [/SUP], Ali Saffaei[SUP] 6 [/SUP], Farzaneh Dastan[SUP] 4 5 [/SUP]
Affiliations
Abstract
Introduction: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a therapeutic strategy for the coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS). There are inconclusive data in this regard and causes of VV-ECMO failure are not yet understood well.
Case series: Here, seven patients with COVID-19-induced ARDS who underwent VV-ECMO introduced and causes of VV-ECMO failure discussed. Medical records of seven COVID-19 patients treated with VV-ECMO were retrospectively evaluated to determine the clinical outcomes of VV-ECMO. Oxygenator failure occurred in four patients whom needed to oxygenator replacement. Successful VV-ECMO decannulation was done in three patients, however finally one patient survived.
Conclusions: Hypercoagulability state and oxygenator failure were the most main etiologies for VV-ECMO failure in our study. All patients with COVID-19 undergoing VV-ECMO should be monitored for such problems and highly specialized healthcare team should monitor the patients during VV-ECMO.
Keywords: SARS coronavirus; SARS-CoV infection; acute respiratory distress syndrome; extracorporeal membrane oxygenation; hypercoagulability.
. 2020 Jul 17.
doi: 10.1111/jocs.14867. Online ahead of print.
Extracorporeal membrane oxygenation and COVID-19: The causes of failure
Zargham Hossein Ahmadi[SUP] 1 [/SUP], Alireza Jahangirifard[SUP] 1 [/SUP], Behrooz Farzanegan[SUP] 2 [/SUP], Payam Tabarsi[SUP] 3 [/SUP], Zahra Abtahian[SUP] 4 [/SUP], Atefeh Abedini[SUP] 4 [/SUP], Mehrzad Sharifi[SUP] 1 [/SUP], Amir Naser Jadbabaei[SUP] 1 [/SUP], Yadollah Mafhumi[SUP] 4 [/SUP], Ali Moslem[SUP] 4 [/SUP], Marjan Sistani[SUP] 4 [/SUP], Sahar Yousefian[SUP] 4 5 [/SUP], Ali Saffaei[SUP] 6 [/SUP], Farzaneh Dastan[SUP] 4 5 [/SUP]
Affiliations
- PMID: 32678961
- DOI: 10.1111/jocs.14867
Abstract
Introduction: Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a therapeutic strategy for the coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS). There are inconclusive data in this regard and causes of VV-ECMO failure are not yet understood well.
Case series: Here, seven patients with COVID-19-induced ARDS who underwent VV-ECMO introduced and causes of VV-ECMO failure discussed. Medical records of seven COVID-19 patients treated with VV-ECMO were retrospectively evaluated to determine the clinical outcomes of VV-ECMO. Oxygenator failure occurred in four patients whom needed to oxygenator replacement. Successful VV-ECMO decannulation was done in three patients, however finally one patient survived.
Conclusions: Hypercoagulability state and oxygenator failure were the most main etiologies for VV-ECMO failure in our study. All patients with COVID-19 undergoing VV-ECMO should be monitored for such problems and highly specialized healthcare team should monitor the patients during VV-ECMO.
Keywords: SARS coronavirus; SARS-CoV infection; acute respiratory distress syndrome; extracorporeal membrane oxygenation; hypercoagulability.